01:37 , Apr 6, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Blood levels of immune cell markers and antibodies could help predict protective responses to Plasmodium CSP -based malaria vaccines. A cohort of 46 healthy volunteers received one of two malaria vaccine regimens...
07:00 , Jul 31, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Malaria Plasmodium falciparum apical membrane antigen 1 (ama1); P. falciparum rhoptry neck protein 2 (Pfron2) In vitro and mouse studies suggest vaccination with a...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Company News

GenVec, Naval Medical Research Center deal

GenVec signed a $3.5 million contract with the research center to support malaria development. GenVec will be responsible for producing its NMRC-M3V-Ad-PfCA malaria vaccine , which uses the company's adenovector delivery technology. The center will...
08:00 , Dec 1, 2011 |  BC Innovations  |  Cover Story

Turning back the malarial hordes

Researchers from the Wellcome Trust Sanger Institute have identified a host receptor, basigin Ok blood group , that allows Plasmodium falciparum to invade erythrocytes and trigger a blood-stage malaria infection. 1 The researchers are now...
07:00 , Sep 19, 2011 |  BC Week In Review  |  Clinical News

FMP2: Phase II data

Researchers at the university and colleagues reported data from a double-blind, Malian Phase II trial in 400 children ages 1-6 showing that 3 doses of the FMP2.1/AS02A malaria vaccine administered on days 0, 30 and...
07:00 , Jul 12, 2010 |  BC Week In Review  |  Clinical News

Malaria vaccine: Phase Ib data

In a Tanzanian Phase Ib trial in 40 healthy volunteers as young as 5 years of age, 2 injections of Mymetics' malaria vaccine were well tolerated and induced specific, long-lasting antibody responses against the apical...
07:00 , Apr 19, 2010 |  BC Week In Review  |  Clinical News

NMRC-M3V-Ad-PfCA malaria vaccine: Phase I/II data

In a Phase I/IIa trial in 21 healthy volunteers, 4 of 15 subjects who were immunized with malaria vaccines remained asymptomatic after challenge with live homologous Plasmodium falciparum sporozoites. The remaining 11 immunized subjects, plus...